Profile
Raymond Kaempfer was the founder of Atox Bio Ltd., which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2011.
He is currently a Member of the European Molecular Biology Organization.
Dr. Kaempfer's former positions include being a Faculty Member at Harvard University and a Professor of Molecular Biology & Cancer Research at The Hebrew University of Jerusalem.
Dr. Kaempfer received a doctorate degree from the Massachusetts Institute of Technology.
Raymond Kaempfer active positions
| Companies | Position | Start |
|---|---|---|
European Molecular Biology Organization | Corporate Officer/Principal | - |
Former positions of Raymond Kaempfer
| Companies | Position | End |
|---|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Founder | - |
Training of Raymond Kaempfer
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
European Molecular Biology Organization | |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
- Stock Market
- Insiders
- Raymond Kaempfer
















